Challenges and opportunities for treating intrahepatic cholangiocarcinoma: targeted therapy

Abstract

Over the last two decades, substantial progress has been made in the scope of molecular targeted therapy, leading to transformative advancements in the treatment of various malignancies, including biliary tract cancer (BTC). BTC represents a heterogeneous group of aggressive tumors with historically poor prognoses. However, recent discoveries of novel molecular alterations in BTC have provided new avenues for targeted therapeutic interventions, exemplified by the approval of pemigatinib, specifically designed for FGFR2 gene fusions or rearrangements in advanced BTC. Furthermore, subsequent regulatory approvals and ongoing clinical trials focusing on specific gene mutations have considerably expanded the array of treatment options available, augmenting the potential for personalized treatment strategies. In light of these developments, this review aims to furnish a comprehensive and up-to-date account of the molecular characteristics and potential targeted therapies in BTC. By presenting insights into novel therapeutic approaches and outlining prospective directions for translational and clinical investigations, this review seeks to contribute to the ongoing progress and optimization of therapeutic approaches in managing BTC.

Keywords

Cholangiocarcinoma / biliary tree cancer / biliary tract cancer / targeted therapy / immunotherapy / next-generation sequencing / bile duct neoplasms / hepatobiliary malignancy / intrahepatic cholangiocarcinoma

References

[1] Banales JM,Carpino G.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nat Rev Gastro Hepat2016;13:261-80

[2] Nagorney DM,Farnell MB,Ilstrup DM.Outcomes after curative resections of cholangiocarcinoma.Arch Surg1993;128:871-7; discussion 877-9

[3] Rizzo A.Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review.Cancer Treat Res Commun2021;27:100354

[4] Lamarca A,Wasan HS.on behalf of the Advanced Biliary Cancer (ABC) Working GroupABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.JCO2019;37:4003

[5] Ramírez-Merino N,Cortés-Funes H.Chemotherapy for cholangiocarcinoma: An update.World J Gastrointest Oncol2013;5:171-6 PMCID:PMC3731530

[6] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81

[7] Oh D,Qin S.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.NEJM Evidence2022;1.

[8] Lowery MA,Jordan E.Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention.Clin Cancer Res2018;24:4154-61 PMCID:PMC6642361

[9] Abou-Alfa GK,Javle MM.Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020;21:796-807 PMCID:PMC7523268

[10] Montal R,Montironi C.Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.J Hepatol2020;73:315-27 PMCID:PMC8418904

[11] Ross JS,Gay L.New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.Oncologist2014;19:235-42 PMCID:PMC3958461

[12] Li W,Yin F.BRAF mutation in Chinese biliary tract cancer patients.JCO2020;38:e16678-e16678

[13] Mondaca S,Xu C.Genomic characterization of ERBB₂-driven biliary cancer and a case of response to ado-trastuzumab emtansine.JCO Precis Oncol2019;3:PO.19.00223 PMCID:PMC7446346

[14] Thein KZ,Banks KC.Identification of KRAS^G12C mutations in circulating tumor DNA in patients with cancer.JCO Precis Oncol2022;6:e2100547 PMCID:PMC9365336

[15] Demols A,Charry M.NTRK gene fusions in biliary tract cancers.JCO2020;38:574

[16] Parimi V,Danziger N.Genomic landscape of 891 RET fusions detected across diverse solid tumor types.NPJ Precis Oncol2023;7:10 PMCID:PMC9870857

[17] Yu J,Huang Q,Xiong X.Rare DNA mismatch repair-related protein loss in patients with intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma and their response to immunotherapy.Cancer Manag Res2021;13:4283-90 PMCID:PMC8183674

[18] Silva VW,Daniel TD.Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency.Chin Clin Oncol2016;5:62

[19] Shao C,Huang L.Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors.JAMA Netw Open2020;3:e2025109 PMCID:PMC7596577

[20] Tian W,Wang Y.Recent advances of IDH1 mutant inhibitor in cancer therapy.Front Pharmacol2022;13:982424 PMCID:PMC9449373

[21] NCCN clinical practice guidelines in oncology (NCCN Guidelines®) biliary tract cancers, version 2.2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf [Last accessed on 25 Dec 2023]

[22] FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma [Last accessed on 25 Dec 2023]

[23] Study of LY3410738 administered to patients with advanced solid tumors with IDH1 or IDH2 mutations. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04521686 [Last accessed on 25 Dec 2023]

[24] A study of HMPL-306 in advanced solid tumors with IDH mutations. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04762602 [Last accessed on 25 Dec 2023]

[25] A study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT02381886 [Last accessed on 25 Dec 2023]

[26] Gemcitabine and cisplatin with ivosidenib or pemigatinib for the treatment of unresectable or metastatic cholangiocarcinoma. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04088188 [Last accessed on 25 Dec 2023]

[27] Borad M,Shaib W.59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications.Ann Oncol2022;33:S567-8

[28] Hollebecque A,Goyal L.LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial.Ann Oncol2022;33:S1381

[29] Ohba A,Kawamoto Y.Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).JCO2022;40:4006

[30] Harding JJ,Oh DY.HERIZON-BTC-01 study groupZanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.Lancet Oncol2023;24:772-82

[31] Harding JJ,Shih AH.Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition.Cancer Discov2018;8:1540-7 PMCID:PMC6699636

[32] Cleary JM,Daina A.Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.NPJ Precis Oncol2022;6:61 PMCID:PMC9440204

[33] Ornitz DM.The fibroblast growth factor signaling pathway.Wiley Interdiscip Rev Dev Biol2015;4:215-66 PMCID:PMC4393358

[34] Acevedo VD,Spencer DM.Paths of FGFR-driven tumorigenesis.Cell Cycle2009;8:580-8 PMCID:PMC7441526

[35] Silverman IM,Lihou CF.Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.JCO2019;37:4080

[36] Javle MM,Shroff RT.Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).JCO2019;37:4087

[37] Meric-Bernstam F,Hierro C.Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study.Cancer Discov2022;12:402-15 PMCID:PMC9762334

[38] Goyal L,Crolley VE.Targeting FGFR inhibition in cholangiocarcinoma.Cancer Treat Rev2021;95:102170

[39] Farha N,Ullah F.Precision oncology targets in biliary tract cancer.Cancers2023;15:2105 PMCID:PMC10093316

[40] FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR₂ rearrangement or fusion. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion [Last accessed on 25 Dec 2023]

[41] Abou-Alfa GK,Hollebecque A.Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol2020;21:671-84 PMCID:PMC8461541

[42] Vogel A,Hollebecque A.O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202.Ann Oncol2022;33:S379

[43] Bekaii-Saab TS,Van Cutsem E.FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Future Oncol2020;16:2385-99 PMCID:PMC9892961

[44] FDA grants accelerated approval to futibatinib for cholangiocarcinoma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma [Last accessed on 25 Dec 2023]

[45] Goyal L,Hollebecque A.FOENIX-CCA2 Study InvestigatorsFutibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma.N Engl J Med2023;388:228-39

[46] Goyal L,Hollebecque A.Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.JCO2022;40:4009

[47] Lau DK,Weickhardt A.Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy.Cancer Drug Resist2019;2:568-79 PMCID:PMC8992533

[48] Schaider H.The evolving universe of BRAF mutations in melanoma.Br J Dermatol2017;177:893

[49] Rose AAN.Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.Drugs Today2019;55:247-64

[50] Caputo F,Bardasi C.BRAF-mutated colorectal cancer: clinical and molecular insights.Int J Mol Sci2019;20:5369 PMCID:PMC6861966

[51] Ritterhouse LL.BRAF V600E mutation-specific antibody: A review.Semin Diagn Pathol2015;32:400-8

[52] Subbiah V,Élez E.Dabrafenib plus trametinib in patients with BRAF^V600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Lancet Oncol2020;21:1234-43

[53] FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid [Last accessed on 25 Dec 2023]

[54] Petitjean A,Borresen-Dale AL,Olivier M.TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.Oncogene2007;26:2157-65

[55] Rizos H,Pupo GM.BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.Clin Cancer Res2014;20:1965-77

[56] Shi H,Kong X.Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.Cancer Discov2014;4:80-93 PMCID:PMC3936420

[57] Van Allen EM,Sucker A.The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.Cancer Discov2014;4:94-109 PMCID:PMC3947264

[58] Shi H,Kong X.Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.Nat Commun2012;3:724 PMCID:PMC3530385

[59] Wagle N,Berger MF.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.J Clin Oncol2011;29:3085-96 PMCID:PMC3157968

[60] Long GV,Menzies AM.Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.Nat Commun2014;5:5694

[61] Wang B,Zhang G.Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Oncogene2021;40:5590-9 PMCID:PMC8445818

[62] Pópulo H,Soares P.The mTOR signalling pathway in human cancer.Int J Mol Sci2012;13:1886-918 PMCID:PMC3291999

[63] Guertin DA.Defining the role of mTOR in cancer.Cancer Cell2007;12:9-22

[64] Iqbal N.Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications.Mol Biol Int2014;2014:852748 PMCID:PMC4170925

[65] Ayasun R,Sahin I.The role of HER2 status in the biliary tract cancers.Cancers2023;15:2628 PMCID:PMC10177412

[66] Galdy S,McNamara MG.HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?.Cancer Metastasis Rev2017;36:141-57 PMCID:PMC5385197

[67] Varga Z,Ramach C,Moch H.Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.BMC Cancer2013;13:615 PMCID:PMC3879657

[68] Junttila TT,Parsons K.Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.Cancer Cell2009;15:429-40

[69] Javle M,Azad NS.Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.Lancet Oncol2021;22:1290-300

[70] Tsurutani J,Krop I.Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple advanced solid tumors.Cancer Discov2020;10:688-701 PMCID:PMC8292921

[71] Vernieri C,Brambilla M.Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives.Crit Rev Oncol Hematol2019;139:53-66

[72] Zhao D,Chao J.Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.J Hematol Oncol2019;12:50 PMCID:PMC6525398

[73] Chen C,Corallo S,Goyal L.Overcoming resistance to targeted therapies in gastrointestinal cancers: progress to date and progress to come.Am Soc Clin Oncol Educ Book2020;40:161-73

[74] Kwak EL,Siravegna G.Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer.Cancer Discov2015;5:1271-81 PMCID:PMC4670804

[75] Pietrantonio F,Morano F.HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.Int J Cancer2016;139:2859-64

[76] Seo S,Park YS.Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).Gastric Cancer2019;22:527-35

[77] Harding JJ,Shah RH.Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.Nat Commun2023;14:630 PMCID:PMC9902444

[78] Vikis HG,Furegato M.Mapping the epidemiologic characteristics of cancer patients with NTRK gene fusions: a real-world analysis of the cerner enviza eletronic health records (EHR) database.JCO2022;40:e15123

[79] U.S. Food & Drug Administration. FDA Approves larotrectinib for solid tumors with NTRK gene fusions. Available from: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions [Last accessed on 25 Dec 2023]

[80] U.S. Food & Drug Administration. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc [Last accessed on 25 Dec 2023]

[81] Drilon AE,van Tilburg CM.Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.JCO2022;40:3100

[82] Doebele RC,Paz-Ares L.trial investigatorsEntrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.Lancet Oncol2020;21:271-82 PMCID:PMC7461630

[83] Krzakowski MJ,Cousin S.Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive ( NTRK -fp) solid tumors.JCO2022;40:3099

[84] Kojadinovic A,Mundi PS.Targeting TRK: A fast-tracked application of precision oncology and future directions.Crit Rev Oncol Hematol2021;165:103451

[85] Harada G,Schram AM.Mechanisms of acquired resistance to TRK inhibitors.JCO2022;40:3104

[86] Katayama R,Togashi N.The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.Nat Commun2019;10:3604 PMCID:PMC6688997

[87] Paratala BS,Williams CB.RET rearrangements are actionable alterations in breast cancer.Nat Commun2018;9:4821 PMCID:PMC6240119

[88] Drusbosky LM,Dawar R.Therapeutic strategies in RET gene rearranged non-small cell lung cancer.J Hematol Oncol2021;14:50 PMCID:PMC7995721

[89] Kato S,Marchlik E,Carter JL.RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients.Clin Cancer Res2017;23:1988-97

[90] Subbiah V,Siena S.Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.Nat Med2022;28:1640-5 PMCID:PMC9388374

[91] FDA approves pralsetinib for lung cancer with RET gene fusions. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions [Last accessed on 25 Dec 2023]

[92] FDA approves pralsetinib for RET-altered thyroid cancers. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers#:~:text=On%20December%201%2C%202020%2C%20the,fusion%2Dpositive%20thyroid%20cancer%20who [Last accessed on 25 Dec 2023]

[93] FDA D.I.S.C.O. Burst Edition: FDA approvals of Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET fusion-positive solid tumors, and Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-retevmo-selpercatinib-adult-patients-locally-advanced-or#:~:text=On%20September%2021%2C%202022%2C%20the,who%20have%20no%20satisfactory%20alternative [Last accessed on 25 Dec 2023]

[94] Subbiah V,Konda B.Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.Lancet Oncol2022;23:1261-73

[95] Santoro M,Federico G.RET gene fusions in malignancies of the thyroid and other tissues.Genes2020;11:424 PMCID:PMC7230609

[96] Andrini E,Galvani L.Non-small-cell lung cancer: how to manage RET-positive disease.Drugs Context2022;11:1-12 PMCID:PMC9281974

[97] Rosen EY,Zheng Y.The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.Nat Commun2022;13:1450 PMCID:PMC8933489

[98] Cha JH,Li CW,Hung MC.Mechanisms controlling PD-L1 expression in cancer.Mol Cell2019;76:359-70 PMCID:PMC6981282

[99] Riaz N,Makarov V.Tumor and microenvironment evolution during immunotherapy with nivolumab.Cell2017;171:934-49.e16 PMCID:PMC5685550

[100] Rizvi H,La K.Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing.J Clin Oncol2018;36:633-41 PMCID:PMC6075848

[101] Schumacher TN.Neoantigens in cancer immunotherapy.Science2015;348:69-74

[102] FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors [Last accessed on 26 Jan 2024]

[103] Marabelle A,Lopez J.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol2020;21:1353-65

[104] Schenker M,Richardet M.Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.Cancer Research2022;82:CT022

[105] Li K,Huang L,Zhu X.Microsatellite instability: a review of what the oncologist should know.Cancer Cell Int2020;20:16 PMCID:PMC6958913

[106] FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors. Available from: https://www.merck.com/news/fda-converts-to-full-approval-indication-for-keytruda-pembrolizumab-for-certain-adult-and-pediatric-patients-with-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient/ [Last accessed on 25 Dec 2023]

[107] Andre T,Curigliano G.Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.JCO2021;39:9S

[108] FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors [Last accessed on 25 Dec 2023]

[109] Sangsuwannukul T,Sujjitjoon J.Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.Int Immunopharmacol2020;89:107069

[110] Feng KC,Liu Y.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.J Hematol Oncol2017;10:4 PMCID:PMC5217546

[111] Guo Y,Liu Y.Phase I study of chimeric antigen receptor-modified T Cells in patients with EGFR-positive advanced biliary tract cancers.Clin Cancer Res2018;24:1277-86

[112] Hassan R,Oh DY.Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.JCO2023;41:8537-8537

[113] Morash M,Beltran H,Pathak J.The role of next-generation sequencing in precision medicine: a review of outcomes in oncology.J Pers Med2018;8:30

[114] Ramón Y Cajal S,Capdevila C.Clinical implications of intratumor heterogeneity: challenges and opportunities.J Mol Med2020;98:161-77 PMCID:PMC7007907

[115] Wu P,Su M.Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment.Front Cell Dev Biol2021;9:641469 PMCID:PMC7957022

[116] Nong S,Xiang Y.Metabolic reprogramming in cancer: Mechanisms and therapeutics.MedComm2023;4:e218 PMCID:PMC10041388

[117] Sabnis AJ.Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology.Trends Mol Med2019;25:185-97 PMCID:PMC6401263

[118] Carpizo DR.Management and extent of resection for intrahepatic cholangiocarcinoma.Surg Oncol Clin N Am2009;18:289-305, viii

[119] Buettner S,Ejaz A.The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-a multi-institutional analysis.J Surg Oncol2017;115:312-8

[120] Mason MC,Tzeng CD.Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience.Ann Surg Oncol2021;28:6725-35

[121] Utuama O,Dagne G.Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: a propensity score survival analysis supporting use in patients with high-risk disease.Ann Surg Oncol2021;28:1939-49

[122] Sutton TL,Walker BS.Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma.Am J Surg2021;221:1182-7

[123] Preoperative nab-paclitaxel, cisplatin, and gemcitabine chemotherapy with or without infigratinib targeted therapy for the treatment of resectable intrahepatic cholangiocarcinoma, the OPTIC trial. Available from: https://clinicaltrials.gov/study/NCT05514912?cond=targeted%20neoadjuvant%20cholangiocarcinoma&rank=1 [Last accessed on 25 Dec 2023]